Otitis media (OM) is one of the commonest infections in childhood and a frequent reason for prescribing antibacterials in infancy. However, the increase in prevalence of antibacterial-resistant respiratory bacterial pathogens has not been matched by the development of new antibacterial agents. Bacterial vaccine strategies aim to prevent OM directly and to reduce nasopharyngeal carriage of pneumococci, thereby reducing the likelihood of developing acute OM. Complete protection against OM would require an approach targeting both bacterial and viral agents.
Immunisation with a pneumococcal conjugate vaccine provides protection against acute OM caused by pneumococcal serotypes included in the vaccine, reduces serotype-specific pneumococcal carriage, and reduces carriage of penicillin-resistant pneumococci. However, an increase in non-vaccine serotype OM has been observed in vaccinated children, which may limit the overall effectiveness of this vaccine. New vaccines targeting non-typablc Haemophilus influenzae and Mycoplasma catarrhalis are in the early stages of development. Efficacy studies with influenza vaccine have shown the most promising results to date in terms of overall reduction in OM episodes.
A more substantial reduction in the burden of OM in childhood would require a combination of vaccines that are effective against the bacterial and viral pathogens involved and that can be administered early in infancy.
Influenza Respiratory Syncytial Virus Otitis Medium Acute Otitis Medium Pneumococcal Conjugate Vaccine
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access
No sources of funding were used in the preparation of this manuscript. There are no potential conflicts of interest.
Nelson WI, Kennedy DL, Lao CS, et al. Out-patient systemic anti-infective use by children in the United States: 1977 to 1986. Pediatr Infect Dis J 1988; 7: 505–9PubMedCrossRefGoogle Scholar
Vernon-Feagans L. Impact of otitis media on speech, language, cognition, and behaviour. In: Rosenfeld RM, Bluestone CD, editors. Evidence-based otitis media. Hamilton (ON): Decker, 1999: 353–73Google Scholar
Gates G. Cost-effectiveness considerations in otitis media treatment. Otolaryngol Head Neck Surg 1996; 4: 525–30CrossRefGoogle Scholar
Paradise JL, Rockette HE, Colborn DK, et al. Otitis media in 2253 Pittsburgh-area infants: prevalence and risk factors during the first two years of life. Pediatrics 1997; 99(3): 318–33PubMedCrossRefGoogle Scholar
Owen MJ, Baldwin CD, Swank PR, et al. Relation of infant feeding practices, cigarette smoke exposure, and group child care to the onset and duration of otitis media with effusion in the first two years of life. J Pediatr 1993; 123(5): 702–11PubMedCrossRefGoogle Scholar
Leach AJ, Boswell JB, Asche V, et al. Bacterial colonization of the nasopharynx predicts very early onset and persistence of otitis media in Australian aboriginal infants. Pediatr Infect Dis J 1994; 13(11): 983–9PubMedCrossRefGoogle Scholar
Giebink GS. The microbiology of otitis media. Pediatr Infect Dis J 1989; 8 (1 Suppl.): S18-20Google Scholar
Ruuskanen O, Arola M, Hekkinen T, et al. Viruses in acute otitis media: increasing evidence for clinical significance. Pediatr Infect Dis J 1991; 10(6): 425–7PubMedCrossRefGoogle Scholar
Teele DW, Klein JO, Bratton L, et al. Use of pneumococcal vaccine for prevention of recurrent acute otitis media in infants in Boston. The Greater Boston Collaborative Otitis Media Study Group. Rev Infect Dis 1981; 3 Suppl. 3: S113-8Google Scholar
Makela PH, Leinonen M, Pukander J, et al. A study of the pneumococcal vaccine in prevention of clinically acute atttacks of recurrent otitis media. Rev Infect Dis 1981; 3 Suppl. 3: S124-32Google Scholar
Shurin PA, Rehmus JM, Johnson CE, et al. Bacterial poly-saccharide immune globulin for prophylaxis of acute otitis media in high-risk children. J Pediatr 1993; 123(5): 801–10PubMedCrossRefGoogle Scholar
Shahid NS, Steinhoff MC, Hoque SS, et al. Serum, breast milk, and infant antibody after maternal immunisation with pneumococcal vaccine. Lancet 1995; 346(8985): 1252–7PubMedCrossRefGoogle Scholar
O’Dempsey TJ, McArdle T, Ceesay SJ, et al. Immunization with a pneumococcal capsular polysaccharide vaccine during pregnancy. Vaccine 1996; 14(10): 963–70PubMedCrossRefGoogle Scholar
Englund JA, Glezen WP. Passive immunization for the prevention of otitis media. Vaccine 2000; 19 Suppl. 1: S116-21Google Scholar
Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 3: 187–95Google Scholar
Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344(6): 403–9PubMedCrossRefGoogle Scholar
Faden H, Duffy L, Wasielewski R, et al. Relationship between nasopharyngeal colonization and the development of otitis media in children. Tonawanda/Williamsville Pediatrics. J Infect Dis 1997; 175(6): 1440–5Google Scholar
Klugman KP, Friedland IR. Antibiotic-resistant pneumococci in pediatric disease. Microb Drug Resist 1995; 1(1): 5–8PubMedCrossRefGoogle Scholar
Spratt BG, Greenwood BM. Prevention of pneumococcal disease by vaccination: does serotype replacement matter? Lancet 2000; 356(9237): 1210–1PubMedCrossRefGoogle Scholar
Obaro SK, Adegbola RA, Banya WA, et al. Carriage of pneumococci after pneumococcal vaccination. Lancet 1996; 348(9022): 271–2PubMedCrossRefGoogle Scholar
Mbelle N, Huebner RE, Wasas AD, et al. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J Infect Dis 1999; 180(4): 1171–6PubMedCrossRefGoogle Scholar
Dagan R. Treatment of acute otitis media: challenges in the era of antibiotic resistance. Vaccine 2000; 19 Suppl. 1: S9-S16Google Scholar
White P, Hermansson A, Svanborg C, et al. Effects of active immunisation with a pneumococcal surface protein (PspA) and of locally applied antibodies in experimental otitis media. ORL J Otorhinolaryngol Relat Spec 1999; 61: 206–11PubMedCrossRefGoogle Scholar
Briles DE, Hollingshead S, Brooks-Walter A, et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 2000; 18(16): 1707–11PubMedCrossRefGoogle Scholar
Ogunniyi AD, Folland RL, Briles DE, et al. Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 2000; 68(5): 3028–33PubMedCrossRefGoogle Scholar
Briles DE, Hollingshead SK, Nabors GS, et al. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 2000; 19 Suppl. 1: S87-95Google Scholar
The Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 (3 Pt 1): 531–7CrossRefGoogle Scholar
Clements DA, Langdon L, Bland C, et al. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med 1995; 149(10): 1113–7PubMedCrossRefGoogle Scholar
Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Engl J Med 1998;338(20): 1405–12PubMedCrossRefGoogle Scholar